DK0719154T3 - Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel - Google Patents

Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel

Info

Publication number
DK0719154T3
DK0719154T3 DK94926591T DK94926591T DK0719154T3 DK 0719154 T3 DK0719154 T3 DK 0719154T3 DK 94926591 T DK94926591 T DK 94926591T DK 94926591 T DK94926591 T DK 94926591T DK 0719154 T3 DK0719154 T3 DK 0719154T3
Authority
DK
Denmark
Prior art keywords
factor viii
therapeutic agent
activated
deficiency
treating
Prior art date
Application number
DK94926591T
Other languages
English (en)
Inventor
Joseph Edward Curtis
Sam Leland Helgerson
Roger L Lundblad
Shu-Len Liu
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Application granted granted Critical
Publication of DK0719154T3 publication Critical patent/DK0719154T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
DK94926591T 1993-09-13 1994-08-26 Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel DK0719154T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/120,894 US5576291A (en) 1993-09-13 1993-09-13 Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
PCT/US1994/009613 WO1995007713A1 (en) 1993-09-13 1994-08-26 Activated factor viii as a therapeutic agent and method of treating factor viii deficiency

Publications (1)

Publication Number Publication Date
DK0719154T3 true DK0719154T3 (da) 2001-11-26

Family

ID=22393146

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94926591T DK0719154T3 (da) 1993-09-13 1994-08-26 Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel

Country Status (10)

Country Link
US (1) US5576291A (da)
EP (1) EP0719154B1 (da)
JP (1) JPH09502714A (da)
AT (1) ATE207759T1 (da)
AU (1) AU686661B2 (da)
CA (1) CA2168332A1 (da)
DE (1) DE69428905T2 (da)
DK (1) DK0719154T3 (da)
ES (1) ES2166783T3 (da)
WO (1) WO1995007713A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003332A1 (en) * 1993-07-23 1995-02-02 Baxter International Inc. Activated human factor viii and method of preparation
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7253262B2 (en) * 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US7244824B2 (en) * 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US6586573B1 (en) 1999-02-22 2003-07-01 Baxter International Inc. Albumin-free Factor VIII formulations
CA2378751C (en) * 1999-07-13 2012-11-06 Biovitrum Ab Stable factor viii compositions
JP4643783B2 (ja) * 1999-12-24 2011-03-02 一般財団法人化学及血清療法研究所 フォンヴィルブランド因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物
EP1458408B1 (en) 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
CN1671410B (zh) 2002-06-21 2010-05-12 诺和诺德医疗保健公司 因子ⅶ多肽的稳定化固体组合物
JP2006524195A (ja) * 2003-03-18 2006-10-26 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの液状水性医薬組成物
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
KR20060015574A (ko) * 2003-05-23 2006-02-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 용액 중 단백질 안정화
JP4658041B2 (ja) * 2003-06-25 2011-03-23 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの液体組成物
WO2005002615A1 (en) * 2003-07-01 2005-01-13 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
AU2004264282B2 (en) 2003-08-14 2010-10-14 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of Factor VII polypeptides
WO2005055930A2 (en) * 2003-12-03 2005-06-23 University Of Rochester Recombinant factor viii having increased specific activity
MXPA06006886A (es) * 2003-12-19 2006-09-04 Novo Nordisk Healthcare Ag Composiciones estabilizadas de polipeptidos del factor vii.
WO2007005482A1 (en) * 2005-06-30 2007-01-11 Ge Healthcare Bio-Sciences Corp. Detection method for gene expression
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP2150264A4 (en) * 2007-04-26 2014-09-24 Bayer Healthcare Llc STABILIZATION OF LIQUID SOLUTIONS OF A RECOMBINANT PROTEIN FOR FROZEN STORAGE
CN101965409A (zh) * 2007-11-01 2011-02-02 罗切斯特大学 具有增加的稳定性的重组因子viii
ES2706296T3 (es) 2008-11-07 2019-03-28 Univ Connecticut Formulaciones de Factor VIII
NZ628987A (en) 2009-02-03 2015-11-27 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
WO2011028228A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
US20130017997A1 (en) * 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
CN104487452A (zh) 2012-02-15 2015-04-01 阿穆尼克斯运营公司 因子viii组合物及其制备和使用方法
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
EP3292407A4 (en) * 2015-05-06 2019-01-02 Prescient Medicine Holdings, LLC Development of novel automated screening method for detection of fviii inhibitors
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2460305A2 (fr) * 1979-06-29 1981-01-23 Merieux Inst Procede de preparation d'un concentre de facteur viii
US4386068A (en) * 1980-02-26 1983-05-31 Cutter Laboratories, Inc. Antihemophilic factor concentrate and method for preparation
AT369263B (de) * 1980-08-27 1982-12-27 Immuno Ag Verfahren zur herstellung eines faktor viii(ahf) -hochkonzentrates
US4857635A (en) * 1983-03-31 1989-08-15 Scripps Clinic And Research Foundation Factor VIII coagulant polypeptides and monoclonal antibodies tof them
US4649132A (en) * 1983-03-31 1987-03-10 Scripps Clinic And Research Foundation Treatment of Factor VIII inhibitors
US5101016A (en) * 1983-03-31 1992-03-31 Scripps Clinic And Research Foundation Factor VIII coagulant polypeptides and monoclonal antibodies to them
ZA842418B (en) * 1983-03-31 1984-11-28 Scripps Clinic Res Factor viii coagulant polypeptides and monoclonal antibodies to them
US4657894A (en) * 1983-03-31 1987-04-14 Scripps Clinic & Research Foundation New factor VIII coagulant polypeptides
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4508709A (en) * 1983-12-05 1985-04-02 Armour Pharmaceutical Company Process for purifying factor VIII:C
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
DK525384D0 (da) * 1984-11-05 1984-11-05 Nordisk Insulinlab Praeparat paa basis af faktor viii til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadan praeparat
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
ATE72838T1 (de) * 1985-04-12 1992-03-15 Genetics Inst Neue prokoagulierungsproteine.
US4769336A (en) * 1985-05-24 1988-09-06 Scripps Clinic And Research Foundation Treatment of factor VIII inhibitors
US4758657A (en) * 1985-07-11 1988-07-19 Armour Pharmaceutical Company Method of purifying Factor VIII:C
US4980456A (en) * 1987-04-06 1990-12-25 Scripps Clinic And Research Foundation Recombinant factor VIIIC derived fragments
CA1331157C (en) * 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
IL86693A (en) * 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins that have the activity IIIV of the blood, a process for their preparation that uses cells are produced through genetic engineering and pharmaceutical preparations that contain them
US4795806A (en) * 1987-07-16 1989-01-03 Miles Laboratories, Inc. Phospholipid affinity purification of Factor VIII:C
US4981951A (en) * 1988-04-14 1991-01-01 Miles Inc. Lectin affinity chromatography of factor VIII
US5149687A (en) * 1991-04-01 1992-09-22 United Technologies Corporation Method for making oriented bismuth and thallium superconductors comprising cold pressing at 700 MPa

Also Published As

Publication number Publication date
WO1995007713A1 (en) 1995-03-23
EP0719154A1 (en) 1996-07-03
AU7638094A (en) 1995-04-03
JPH09502714A (ja) 1997-03-18
ATE207759T1 (de) 2001-11-15
DE69428905T2 (de) 2002-05-29
US5576291A (en) 1996-11-19
CA2168332A1 (en) 1995-03-23
AU686661B2 (en) 1998-02-12
DE69428905D1 (de) 2001-12-06
EP0719154B1 (en) 2001-10-31
ES2166783T3 (es) 2002-05-01

Similar Documents

Publication Publication Date Title
DK0719154T3 (da) Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel
NO961888L (no) Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer av metallproteinaser
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
DE60139078D1 (de) Plasminogen aktivator zur verhinderung von horn- und subepithelialeintrübung nach laser-sehkraftkorrektur-chirurgie
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
SE9404196D0 (sv) New antithrombotic formulation
DK0723444T3 (da) Levobupivacain, som er egnet til behandling af kronisk smerte
ATE444086T1 (de) Therapeutische zusammensetzungen und verfahren zur behandlung von periodontitis mit entzündunshemmenden mitteln
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
DK71387A (da) Terapeutisk middel til behandling af psoriasis
ATE78171T1 (de) Gangliosidgemisch zur verwendung als therapeutisches hilfsmittel zur schmerzunterdrueckung bei peripheren neuropathien.
DE69310528T2 (de) Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft
SE9603725D0 (sv) New teatment
YU49422B (sh) Upotreba inhibitora ugljenične anhidraze za proizvodnju medikamenata za tretiranje makularnog edema ili makularne degeneracije izazvane starošću
AU1023497A (en) Tissue factor - kunitz domain fusion proteins as factor viia inhibitors
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
ATE190843T1 (de) Zubereitungen zur behandlung von impotenz, die ein alpha-1 inhibitor und ein alpha-2 inhibitor enthalten
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
EE9700350A (et) COMT-inhibiitorite uus kasutamine ja diabeetiliste vaskulaarsete häirete ärahoidmise meetod
ATE200624T1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
DE69304266D1 (de) Zusammensetzung enthaltend Dibucaine-Hydrochlorid, ein Salicylat, Calciumbromid und ein antiphlogistisches steroid zur Schmerzbekämpfung